相关实验视频

Updated: Jun 23, 2025

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

描述MRI放射学和AHR表达之间的关系,并推导出用于质母细胞瘤预后评估的预测模型

Chen Liu¹, Dingkang Xu², Limin Meng³

¹Department of Radiotherapy, Air Force Medical Center, The Fourth Military Medical University, PLA, No 30. Fucheng Road, Haidian District, Beijing, 100142, China.

|June 19, 2024

概括

放射学模型可以预测质母细胞瘤患者的质碳化合物受体 (AHR) 表达和预后. 这种非侵入性方法有助于临床评估和精确治疗质瘤.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
基因组学就是基因组学.

背景情况:

基碳化合物受体 (AHR) 是一种与质瘤相关的分子标记物,也是潜在的治疗点.
建立非侵入性方法来预测AHR对于质瘤管理至关重要.

研究的目的:

开发非侵入性放射学模型,用于预测质母细胞瘤中的AHR表达.
评估AHR表达和放射性特征在质母细胞瘤患者的预后价值.

主要方法:

利用TCGA和TCIA对质母细胞瘤患者的对比度增强的T1加权MRI数据.
使用最大相关性和最小冗余性 (mRMR) 和递归特征消除 (RFE) 来进行特征选择.
使用逻辑回归 (LR) 和支持向量机器 (SVM) 构建预测模型.

主要成果:

较高的AHR表达与较差的质母细胞瘤预后相关 (P<0.05).
AHR仍然是预后不佳的独立风险因素 (HR: 1.61,P<0.05).
LR和SVM模型的AUC分别为0.887和0.872;放射性评分预测了整体存活率 (HR:3.931,P<0.05).

结论:

开发的放射学模型有效地预测了质母细胞瘤的AHR表达和预后.
这些模型为临床评估和质瘤个性化治疗策略提供了宝贵的工具.

关键词:

阿里碳水化合物受体是什么?质母细胞瘤 (glioblastoma) 是一个免疫透分析机器学习是机器学习.无线电学分数的得分是什么

更多相关视频

Author Spotlight: Integrating High-Resolution Intravital Imaging and MRI to Enhance Stereotactic Body Radiation Therapy Planning

Author Spotlight: Integrating High-Resolution Intravital Imaging and MRI to Enhance Stereotactic Body Radiation Therapy Planning

Published on: April 12, 2024

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Magnetic Resonance Imaging Assessment of Carcinogen-induced Murine Bladder Tumors

Published on: March 29, 2019

相关概念视频

Magnetic Resonance Imaging

Magnetic Resonance Imaging

Magnetic resonance imaging (MRI) is a noninvasive medical imaging technique based on a phenomenon of nuclear physics discovered in the 1930s, in which matter exposed to magnetic fields and radio waves was found to emit radio signals. In 1970, a physician and researcher named Raymond Damadian noticed that malignant (cancerous) tissue gave off different signals than normal body tissue. He applied for a patent for the first MRI scanning device in clinical use by the early 1980s. The early MRI...